

HARRIS & HARRIS GROUP INC /NY/  
Form 8-K  
March 07, 2012

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

March 7, 2012 (March 7, 2012)

---

**HARRIS & HARRIS GROUP, INC.**

(Exact name of registrant as specified in its charter)

<b>New York</b>	<b>0-11576</b>	<b>13-3119827</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

---

**1450 Broadway**  
**New York, New York 10018**

(Address of principal executive offices and zip code)

**(212) 582-0900**

(Registrant's telephone number, including area code)

Edgar Filing: HARRIS & HARRIS GROUP INC /NY/ - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

Harris & Harris Group, Inc. (the “Company”) noted the announcement that its portfolio company, Mersana Therapeutics, Inc., entered into a collaboration agreement with Endo Pharmaceutical (NASDAQ: ENDP) to develop next-generation antibody-drug conjugates (ADCs).

The Company also today announced its \$815,000 investment in privately-held OpGen, Inc.

The Company's press releases are attached hereto as Exhibit 99.1 and 99.2.

**Item 9.01. Financial Statements and Exhibits.**

(a) Not applicable.

(b) Not applicable.

(c) Not applicable.

(d) Exhibits.

**Exhibit No. Description**

99.1	Mersana Press Release dated March 7, 2012
99.2	OpGen Press Release dated March 7, 2012



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 7, 2012 HARRIS & HARRIS GROUP, INC.

By: /s/ Douglas W. Jamison  
Douglas W. Jamison  
Chairman and Chief Executive Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Mersana Press Release dated March 7, 2012

99.2 OpGen Press Release dated March 7, 2012